Genocea Biosciences, Inc. GNCA
Day range unavailable
52-week range unavailable
- Revenue (ttm)
- 1.91M
- Shares out
- 58.78M
- Forward P/E
- -0.02
- Beta
- 1.95
- Analysts
- Hold
- Price target
- 3.08 (+3079900.0%)
- Earnings date
- Dec 29, 2022
2Y -1.7894 (-99.97%)
Key statistics
- Enterprise value
- -3.65M
- PEG ratio
- 0.00
- Price / sales
- 0.46
- Price / book
- 0.07
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -31.45M
- Total cash
- 20.14M
- Total debt
- 15.48M
- Return on equity
- -525.78%
- Short % of float
- 3.40%
- 50-day average
- 0.134553
- 200-day average
- 0.978319
Analyst view
Consensus: hold
- Target (low)
- 0.16
- Target (mean)
- 3.08
- Target (high)
- 6.00
- Strong buy0
- Buy3
- Hold1
- Sell0
- Strong sell0
Next earnings
Dec 29, 2022
Expected Dec 29, 2022. Consensus EPS estimate -0.18.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Dec 29, 2022 | Sep 1, 2022 | 0.00 | — | — | — |
| Jun 30, 2022 | Mar 1, 2022 | -0.16 | — | — | — |
| Mar 10, 2022 | Dec 1, 2021 | -0.18 | — | — | — |
| Oct 28, 2021 | Sep 1, 2021 | -0.20 | — | — | — |
| Jul 29, 2021 | Jun 1, 2021 | -0.18 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Apr 29, 2022 | HC Wainwright & Co. | down | Buy | Neutral |
| Apr 29, 2022 | Stifel | down | Buy | Hold |
| Apr 6, 2021 | SVB Leerink | main | — | Outperform |
| Feb 11, 2021 | Needham | main | — | Buy |
| Nov 25, 2020 | Needham | main | — | Buy |
| Nov 25, 2020 | HC Wainwright & Co. | main | — | Buy |
About Genocea Biosciences, Inc.
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- genocea.com
News
71 Biggest Movers From Yesterday 
Stocks That Hit 52-Week Lows On Tuesday 
110 Biggest Movers From Friday - Stocks That Hit 52-Week Lows On Wednesday
Stocks That Hit 52-Week Lows On Friday 
Stocks That Hit 52-Week Lows On Thursday 
28 Stocks Moving in Friday's Pre-Market Session 
22 Stocks Moving in Friday's Pre-Market Session 
Earnings Scheduled For March 10, 2022 - Earnings Scheduled For October 28, 2021
Your note
Sign in to keep a note on GNCA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BASKETT FOREST | Beneficial Owner of more than 10% of a Class of Security | Sale | May 24, 2022 | 0 |
| BEHBAHANI ALI | Director and Beneficial Owner of more than 10% of a Class of Security | Sale | May 24, 2022 | 0 |
| CLARK WILLIAM D | Chief Executive Officer | Sale | Jun 1, 2022 | 304,377 |
| DUVALL DIANTHA | Chief Financial Officer | Sale | Jun 1, 2022 | 75,388 |
| FLECHTNER JESSICA BAKER | Officer | Sale | Jun 1, 2022 | 89,027 |
| FLORENCE ANTHONY A JR | Beneficial Owner of more than 10% of a Class of Security | Sale | May 24, 2022 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| NEA Management Company, LLC | 17.65% | 10,376,936 | 155.65K | Mar 30, 2022 |
| Avoro Capital Advisors LLC | 8.65% | 5,084,184 | 76.26K | Mar 30, 2022 |
| BVF Inc. | 6.83% | 4,012,404 | 60.19K | Mar 30, 2022 |
| Commodore Capital, LP | 5.24% | 3,079,756 | 46.20K | Mar 30, 2022 |
| Point72 Asset Management, L.P. | 4.38% | 2,576,385 | 38.65K | Mar 30, 2022 |
| Kingdon Capital Management LLC | 3.35% | 1,972,056 | 29.58K | Mar 30, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.07% | 1,214,942 | 18.22K | Mar 30, 2022 |
| Vanguard Extended Market Index Fund | 0.48% | 279,637 | 4.19K | Mar 30, 2022 |
| Fidelity Extended Market Index Fund | 0.31% | 184,922 | 2.77K | Apr 29, 2022 |
| iShares Core S&P Total U.S. Stock Market ETF | 0.18% | 106,055 | 1.59K | Apr 29, 2022 |
| iShares Micro Cap ETF | 0.16% | 95,324 | 1.43K | May 30, 2022 |
| Vanguard Institutional Index-Inst Total Stock Market Ind | 0.08% | 47,393 | 710 | Mar 30, 2022 |